Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Asset Writedowns and Impairment (2016 - 2020)

Historic Asset Writedowns and Impairment for Ernexa Therapeutics (ERNA) over the last 11 years, with Q4 2020 value amounting to $10000.0.

  • Ernexa Therapeutics' Asset Writedowns and Impairment fell 9753.69% to $10000.0 in Q4 2020 from the same period last year, while for Sep 2023 it was $10000.0, marking a year-over-year decrease of 9834.71%. This contributed to the annual value of $800000.0 for FY2022, which is N/A changed from last year.
  • As of Q4 2020, Ernexa Therapeutics' Asset Writedowns and Impairment stood at $10000.0, which was down 9753.69% from $189000.0 recorded in Q1 2020.
  • Ernexa Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $406000.0 during Q4 2019, with a 5-year trough of -$3000.0 in Q2 2019.
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $25000.0 (2017), whereas its average is $53352.9.
  • Within the past 5 years, the most significant YoY rise in Ernexa Therapeutics' Asset Writedowns and Impairment was 152400.0% (2019), while the steepest drop was 11071.43% (2019).
  • Ernexa Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $7000.0 in 2016, then skyrocketed by 257.14% to $25000.0 in 2017, then changed by 0.0% to $25000.0 in 2018, then skyrocketed by 1524.0% to $406000.0 in 2019, then crashed by 97.54% to $10000.0 in 2020.
  • Its last three reported values are $10000.0 in Q4 2020, $189000.0 for Q1 2020, and $406000.0 during Q4 2019.